Biogen Seeks Dialogue With US CMS About Alzheimer's Drug Coverage Decision

Biogen's chief executive officer on Thursday said the company wants a dialogue with the CMS ahead of a final decision on coverage of its controversial Alzheimer's disease drug in April.
Reuters Health Information

source https://www.medscape.com/viewarticle/966555?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?